Completed
Agitation in Alzheimer's Disease
Led by National Institute on Aging (NIA) · Updated on 2005-06-24
N/A
Participants Needed
16
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.
CONDITIONS
Brief Title
Agitation in Alzheimer's Disease
Who Can Participate
Eligibility Criteria
Inclusion Criteria:
- Memory problem consistent with a probable diagnosis of Alzheimer's disease (AD)
- Agitation symptoms for at least the past 2 weeks
- Patient has caregiver who can participate
- Patient lives in the same household as the caregiver
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here